Corticosteroid use and increased CXCR2 levels on leukocytes are associated with lumacaftor/ivacaftor discontinuation in cystic fibrosis patients homozygous for the F508del CFTR mutation
Table 7
A regression model combining clinical and molecular markers accurately distinguishes individuals who discontinued luma/iva treatment in our patient cohort.